Message Font: Serif | Sans-Serif
 
No. of Recommendations: 0
TETRA GROWING OUT OF THE SHADOWS OF APHRIA

TETRA PARTNER LIST GROWING STRONG:
Tetra recently signed a major deal with another very large company bringing its number of total partners to now over one dozen: Altus Formulation, a Quebec based drug formulation development company with patented drug delivery technologies for time release and for ease of intravenous and oral delivery of formerly highly insoluble molecules; Altasciences Clinical Research (Algorithme Pharma); Aphria (NYSE:APHA), a cannabis producer; Azevedos, a 200-year old Portuguese pharamceutical brand dealing in over 80 countries in business areas from A to Z and over 300 Marketing Authorizations; Crescita (TSX: CTX), a commercial dermatology company with patented delivery platforms for prescription and non-prescription skincare products; Intelgenx, a partner which has an advanced technology (Adversa), time-released form of the cannabinoid Dronabinol XL for anorexia, nausea and vomiting, which research indicates improves bioavailability and reduces gastro-intestinal side effects compared to traditional Dronabinol effects; Kamada, a company with two FDA-approved products and an Israeli-based distribution segment setting up to distribute Tetra's PPP001 in Israel; McGill University, is partnering with Tetra on a National Sciences & Engineering Research Council funded research study developing consumer cannabinoid products; NSERC leading edge research funding leads to world firsts in the marketplace; Ontario Lung Association, a non-profit that promotes healthy breathing solutions; Panag Pharma, a recently acquired subsidiary of Tetra focused on PPP003 and PPP004 for pain and inflammation treatment with a late stage products ready for commercialization; University of New Brunswick where Tetra and The New Brunswick Health Research Foundation have established and are sponsoring the Health Research Chair in Cannabis at UNB; Genacol, a large natural health products manufacturer with brand products available in more than 40 countries, including Latin America, Europe, Asia, the Middle East, Africa and the United States. In addition, the Genacol trademark is registered in 81 countries worldwide. Genacol has co-developed at least two CBD products with Tetra Bio-Pharma and there are two bottles that are available to view on the Tetra website or social media that are believed ready to go with the October 17th, 2019 new regulations in Canada, a cannabinoid derived CBD oral capsule and a CBD topical cream for treating joint pain and inflammation.

U.S. BASED THORNE NOW A TETRA PARTNER IN A 50-50 JV CALLED CB2 THERAPEUTICS:
Add to this large group of partners Thorne. It's a very large, US health food supplement veteran. (https://ir.tetrabiopharma.com/newsroom/press-releases/news-d...) with Thorne one month ago, announced August 21st, 2019, creating a company called CB2 Therapeutics. Thorne is a U.S.-based health and technology company that for 30 years is a recognized leader in the nutritional supplement industry by providing researched-based, high quality, natural food products. Their product line includes foundational vitamins and minerals, therapeutically-focused nutritional supplements, and sport products certified by the National Sports Foundation (NSF). The spigot is getting ready to pour.

HOW THE JV WORKS:
Both companies have created a true 50-50 joint venture with each partner contributing any and all of their resources necessary to the venture: "all parties grant the joint venture an exclusive, fully-paid, royalty-free license to use their respective intellectual property for global product development and commercialization ... in order to (leverage and increase their ability to) focus on developing compounds for chronic inflammatory conditions with high unmet needs or that are poorly served with existing therapies." Reference: JV article above.

TETRA HAS SLOWLY UNVEILED ITS ATTACK ON INFLAMMATION:
According to Harvard for one decade, and to a large and growing population of doctors, researchers and physicians, inflammation can be found in every condition ever known to afflict mankind, and when it strikes, whatever the condition, it begins to deteriorate. Stopping inflammation is, therefore, absolutely critical to stopping, reversing, alleviating conditions and symptoms of problematic medical conditions. Inflammation is now becoming a key buzzword in the everyday doctor's office setting. Tetra's press is now clearly targeting inflammation, which includes so many markets it's astronomical, and they are doing so with cutting edge cannabinoid, cannabis products that are a cut above the rest.

TETRA AND THORNE: PATENTS: OCTOBER 17TH, 2019:
Tetra and Thorne are on the leading edge of this major advance in medical knowledge and treatment research and product development. Tetra has ALMOST TWENTY patents they own or control and the list is growing. They have several products almost out of final clinical trials and readying for commercialization. At least one is just waiting for Health Canada regulations to change in October. See here: https://www.ctvnews.ca/canada/new-laws-and-rules-coming-into... "Sale of edible, (or topical or extract) cannabis products: The production and sale of edible cannabis, cannabis extracts, and cannabis topicals will be legal in Canada no later than Thursday, October 17, 2019. Yes, that's three weeks away at most. I expect major announcements from Tetra on October 17th, then, or if Health Canada does it earlier than that, then on that date Tetra is very likely to release the major news they have about their participation in the commercialization of these products they have ready. They recently announced they just concluded a highly successful final clinical trial on a topical cannabis solution for skin conditions approved by Health Canada very recently. A timely solution! Expect news on that.

TETRA HINTS SOME OF THEIR RESEARCH RESULTS ARE CLOSER THAN PEOPLE THINK:
Tetra is saying on their website in a presentation that "Cannabis Drug Research Results Are Closer Than You Think". To me that's a statement to investors and anyone else who is listening that I take to mean they are hinting about their own research. Look at their pipeline in clinical trials and they've got one Panag subsidiary just successfully completing its final stage clinical trial, plus a couple more at the end stages of theirs. That would match what the company has been saying the last year or so. It is a recent direct quote from Tetra Bio-Pharma. If you want to find it, go to their website here: https://tetrabiopharma.com/patient-resource/ or on social media here: https://www.facebook.com/photo.php?fbid=10219752577224463&am... to see the actual document image.

DOCTORS, PHYSICIANS, FDA, HC AND EMA PROVIDING GREAT FEEDBACK TO TETRA:
According to the company, these research results will give "the evidence requested (required and demanded) by the authorities (like the FDA, HC and EMA agencies in N. America and Europe) and doctors to safely treat ill people." In this statement, Tetra is defining what they are hearing from the doctors and physicians they have been surveying in North America and Europe over the last four years about what they need to see, to know, to understand, in order to begin actively promoting cannabis drugs to their patients. You have to realize not even 10% of doctors at this time are advising patients to take cannabis. And that is nothing to ignore at this time.

FIRST TIME DRUG APPROVAL AND COMMERCIALIZATION FOR A RECENT STARTUP CREATES A PARADIGM SHIFT:
With drug approval for a company, especially one that is so well known among the patient population, it creates a paradigm shift in the opportunity to commercialize your product knowing it will be well-received. You also have a monopoly on whichever drug it is these agencies approve. You are the one the channel resellers must come to in order to obtain it. It is, in fact, a key change that will occur once the three big drug agencies approve the coming cannabis drugs from Tetra BioPharma. Why? Another reason? Think about regular drugs that you know of how you found out about them. You found out from the doctor when they mentioned a drug you never heard of before. With cannabis, everybody and his dog knows about cannabis now. So you have that whole barrier removed so that you don't have to introduce and familiarize patients with it. There's seldom been a drug that can say that in the history of medicine. Nobody ever knows what drugs the doctor is telling them about when it's new. Nobody. They always have to explain it. It's a major reason why the pharmacists are charged with advising patients when they pick it up to describe all about it. Not so with cannabis nearly to that extent. They market of patient consumers already knows about CBD, THC, what it's being used for. They just need it to be approved for their doctor to us and their insurance to approve.

BOTTOM LINE:
Bottom line, when Tetra's first product is ready to go, very very soon, the marketing for it's already been done 95%. It's going to really be something. The price is at a 3 year low and I believe oversold greatly, and investor patience will be greatly rewarded. I remember when Globalscape went way down below a dollar, but it's now close to $12.00. Patience can make the big catch and this looks like a big catch in the making.
Print the post  

Announcements

What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.